|
|||||||
|
BioTime is moving forward on it’s $53 million deal to purchase stem cell research and development assets from Geron Corporation. (Google Street View) BioTime, Inc., an Alameda-based biotechnology company, announced today that it has signed a deal with Geron Corporation to acquire intellectual property and other assets related to human embryonic stem cell programs [...]
BioTime is moving forward on it’s $53 million deal to purchase stem cell research and development assets from Geron Corporation. (Google Street View) Alameda biotech firm BioTime announced late yesterday that it is making progress on its efforts to acquire stem cell research and development assets from Geron Corporation of Menlo Park. [...]
BioTime of Alameda has made a bid for stem cell research assets owned by Geron Corporation. Alameda’s BioTime has issued an open letter to shareholders of Geron Corporation, encouraging them to support a $53 million deal that would see a BioTime subsidiary acquire stem cell research and development assets from Geron. [...] BioTime, a biotech company based in Alameda announced second quarter financial results yesterday. For the quarter ended June 30, 2012, the company realized a net loss of $5.5 million or $0.11 per share. For the first six months of this year, the company reported a loss of $10.4 million, worse than the $7.6 million loss [...] BioTime, an Alameda-based biotechnology company, announced this week that it will market its stem cell lines in Asia, through an agreement with Shanghai Genext Medical Technology Company. [...] BioTime Inc., a biotech company based in Alameda’s Harbor Bay Business Park, is expanding their corporate headquarters. [...] |
 |
||||||
|
Copyright © - All Rights Reserved Powered by WordPress & Atahualpa |
|||||||
Twitter Feed
Recent Comments